Welcome to our dedicated page for Achilles Therapeutics plc American Depositary Shares news (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics plc American Depositary Shares stock.
Achilles Therapeutics plc (NASDAQ: ACHL) is a clinical-stage biopharmaceutical company dedicated to developing next-generation, AI-powered precision T-cell therapies for the treatment of solid tumors. The company's innovative approach harnesses the immune system to target and destroy cancer cells by focusing on clonal neoantigens—unique protein markers present on all cancer cells but absent from healthy tissue.
Achilles Therapeutics employs advanced DNA sequencing and its proprietary PELEUS™ bioinformatics platform to identify these clonal neoantigens. This precision allows for the development of tailored T-cell-based product candidates aimed at these specific cancer markers. The company has two ongoing Phase I/IIa clinical trials: CHIRON for advanced non-small cell lung cancer (NSCLC) and THETIS for recurrent or metastatic melanoma.
Recent achievements include the progress in clinical trials, with additional clinical and translational science data expected in the fourth quarter of 2023. The strong cash position of $158.5 million supports operations into mid-2025. The company continues to refine its manufacturing processes, notably the VELOS™ platform, which has significantly improved T-cell doses.
A notable collaboration with Arcturus Therapeutics aims to combine Achilles' AI-driven technology with Arcturus' self-amplifying mRNA platform to develop personalized cancer vaccines. This research highlights Achilles' commitment to leveraging cutting-edge technologies for cancer treatment.
Achilles has also received significant patents and regulatory recognitions, including a US patent for its neoantigen immunogenicity prediction and an Innovation Passport from the UK MHRA, underlining its leadership in the bioinformatics and immunotherapy sectors.
Looking ahead, Achilles plans to report more clinical data in the first quarter of 2024 and continue its focus on optimizing its T-cell therapies and expanding its technological capabilities.
Achilles Therapeutics (NASDAQ: ACHL) has announced significant progress in its clinical trials. The first patient received a personalized clonal neoantigen-reactive T cell (cNeT) in the CHIRON trial for advanced non-small cell lung cancer (NSCLC). Following a positive review by the Independent Data Safety Monitoring Committee, enrollment for THETIS Cohort B has also begun, testing cNeT with a PD-1 inhibitor for metastatic melanoma. Results from both trials are anticipated in the second half of 2022, highlighting the company's commitment to treating difficult cancers.
Achilles Therapeutics (NASDAQ: ACHL) announced the appointment of Bernhard Ehmer as a Non-Executive Director, enhancing the Board with his extensive experience in R&D and regulatory affairs. Previously, Ehmer held leadership roles in several biotech firms, including CEO of Biotest AG. The company also reported the resignation of Derek DiRocco from the Board on May 3, 2022. This transition comes as Achilles focuses on advancing its precision T cell therapies targeting cancer, supported by its proprietary PELEUS™ bioinformatics platform.
Achilles Therapeutics (NASDAQ: ACHL) announced its participation in two key conferences this May. The Bank of America 2022 Healthcare Conference will be held from May 9-13 in Las Vegas, where CEO Iraj Ali will speak on May 11 at 4:00 PM PT. Additionally, at the H.C. Wainwright Global Investment Conference from May 23-26 in Miami, VP Lee Stern will present on May 24 at 5:00 PM ET. Achilles focuses on developing precision T cell therapies for solid tumors, utilizing its proprietary PELEUS™ bioinformatics platform.
Achilles Therapeutics (NASDAQ: ACHL) announced a significant expansion in clinical manufacturing capabilities in the UK and US. The UK facility at the Cell & Gene Therapy Catapult has achieved GMP certification and will support ongoing Phase I/IIa trials with a new capacity for 600 doses of personalized cNeT therapies. The US partnership with the Center for Breakthrough Medicines will enhance supply chain operations with up to 200 doses. This expansion is expected to strengthen clinical operations and support future growth in treating advanced cancers.
Achilles Therapeutics (NASDAQ: ACHL) announced its participation in key conferences throughout April 2022 to discuss its innovative T cell therapies for solid tumors. On April 5, CEO Iraj Ali will join a panel at the Accelerating Bio-Innovation 2022 in Cambridge. Subsequently, he will present at the Needham Virtual Healthcare Conference on April 12, and attend the Kempen Life Sciences Conference on April 20 for investor meetings. A significant KOL webcast on April 14 will feature Professor Charles Swanton discussing the implications of the TRACERx study for personalized cancer treatment.
Achilles Therapeutics plc (NASDAQ: ACHL) announces a KOL webcast scheduled for April 14, 2022, at 10:30 AM ET. The event will feature Professor Charles Swanton, who will discuss the TRACERx study's role in identifying clonal neoantigens for personalized T cell therapies. The TRACERx study, with over 3,200 tumor samples from 800 lung cancer patients, is crucial for validating Achilles’ AI-powered PELEUS platform. The webcast will include presentations from key experts and a Q&A session moderated by Dr. Joseph Catanzaro.
Achilles Therapeutics (NASDAQ: ACHL) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference, scheduled for March 15-17, 2022. CEO Iraj Ali will present an overview of the company and its pipeline on March 15 at 8:00 am ET. A live and recorded webcast of the presentation will be accessible via the Achilles website. The company specializes in precision T cell therapies targeting clonal neoantigens, with ongoing Phase I/IIa trials for advanced non-small cell lung cancer and metastatic melanoma.
Achilles Therapeutics (ACHL) reported its Q4 and full-year 2021 financial results, highlighting significant data on its cNeT therapies aimed at treating solid tumors. The company holds $266 million in cash, sufficient to fund operations through mid-2024, including ongoing clinical trials. Notable developments include plans to dose patients with higher-dose cNeT therapies and initiate a tumor archiving program in 2022. They have made advancements in both R&D and manufacturing capabilities, and continue to expand their U.S. presence with a new headquarters in Philadelphia.
Achilles Therapeutics (NASDAQ: ACHL) announced the addition of Dr. Alena Gros and Dr. Ben Creelan to its Scientific Advisory Board. Their expertise in cancer immunology and therapy will support the company's ongoing clinical trials, CHIRON for non-small cell lung cancer and THETIS for melanoma. Dr. Gros brings significant research on T cell responses, while Dr. Creelan is an experienced oncologist focused on lung cancer. This strategic enhancement aims to advance Achilles' precision T cell therapies, utilizing unique patient-specific clonal neoantigens.
Achilles Therapeutics (NASDAQ: ACHL) has announced significant advancements in its personalized T cell therapy programs targeting clonal neoantigens (cNeT). Following regulatory approval, the company will implement a new higher-dose manufacturing process, VELOS Process 2, enhancing production efficiency for clinical trials in the U.S. and Europe. Key 2022 milestones include the acceptance of an IND for head and neck cancer, reporting higher-dose cNeT data, and expanding manufacturing capabilities. These developments promise to advance Achilles' mission in precision cancer treatment while aiming to significantly improve patient outcomes.
FAQ
What is the current stock price of Achilles Therapeutics plc American Depositary Shares (ACHL)?
What is the market cap of Achilles Therapeutics plc American Depositary Shares (ACHL)?
What is Achilles Therapeutics plc?
What are clonal neoantigens?
What clinical trials does Achilles Therapeutics currently have ongoing?
What is the PELEUS™ platform?
What recent achievements has Achilles Therapeutics made?
What is the collaboration with Arcturus Therapeutics about?
What is the financial position of Achilles Therapeutics?
What are the future plans for Achilles Therapeutics?
What regulatory recognitions has Achilles Therapeutics received?
How does Achilles Therapeutics leverage AI in its treatments?
